share_log

Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360 CDx and Guardant360 TissueNext as Companion Diagnostics for Positive Non-Small Cell Lung Cancer

Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360 CDx and Guardant360 TissueNext as Companion Diagnostics for Positive Non-Small Cell Lung Cancer

Guardant Health 和 anHeart Therapeutics 宣布合作开发 Guardant360 CDx 和 Guardant360 TissueNext 作为非小细胞肺癌阳性的伴随诊断工具
Benzinga Real-time News ·  2023/02/02 08:10

Collaboration is Guardant Health's first to explore both tissue- and blood-based assays as companion diagnostics (CDx). Taletrectinib is an investigational ROS1 inhibitor for the treatment of adult patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).

协作是Guardant Health第一个探索组织和血液分析作为伴随诊断(CDX)的公司。̂Taletrectinib是一种研究中的ROS1I抑制剂,用于治疗晚期或转移性ROS1阳性非小细胞肺癌(NSCLC)。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发